Chan-YoungMWongRMacleanL. Epidemiological health study of workers in an aluminium smelter in British Columbia: Effects on the respiratory system. Am Rev Resp Dis1983; 127: 465–9.
2.
McLaughlinAIGKazantzisGKingE. Pulmonary fibrosis and encephalopathy associated with inhalation of aluminium dust. Br J Ind Med1962; 19: 253–63.
3.
AlfreyACMishellJMBurksJ. Syndrome of dyspraxia and multifocal seizures associated with chronic haemodialysis. Trans Am Soc Art Int Organs1972; 18: 257–61.
4.
SchreederMTFaveroMSHughesJR. Dialysis encephalopathy and aluminium exposure: An epidemological analysis. J Chronic Diseases1983; 36: 581–93.
5.
ElliottHLDryburghFFellGS. Aluminium toxicity during regular haemodialysis. Br Med J1978; i: 1101.
6.
BerlyneGMYagilRBen-AriJ. Aluminium toxicity in rats. Lancet1972; i: 564–7.
7.
KlatzoIWisniewskiHStreicherE. Experimental production of neurofibrillary degeneration I. Light microscopic observations. J Neuropathol Exp Neurol1965; 24: 187–99.
8.
PetitTLBiedermanGBJonasPLe BoutellierP. Neurobehavioral development following aluminium administration in infant rabbits. Exp Neurol1985; 88: 640–51.
9.
McKinneyTDBasingerMDawsonEJonesMM. Serum aluminium levels in dialysis dementia. Nephron1982; 32: 53–6.
10.
StarkeyBJTaylorAPWalkerSW. The measurement of aluminium in serum, water, dialysis fluids and biological tissues. In TaylorAP, ed. Aluminium and other trace elements in renal disease.London: Baillière Tindall, 1986; 177–83.
11.
McDermottJRSmithAIWardMK. Brain aluminium concentration in dialysis encephalopathy. Lancet1978; i: 901–4.
12.
BanksWAKastinAJ. Aluminium increases permeability of the blood-brain barrier to some non-peptides. Neuopharmacology1985; 24: 407–12.
13.
LeemingRJBlairJA. Dialysis dementia, aluminium and tetrahydrobiopterin metabolismLancet1979; i: 556.
LaiJCKBlassJP. Inhibition of brain glycolysis by aluminium. J Neurochem1984; 42: 438–46.
16.
SiegelNHangA. Aluminium interaction with calmodulin. Evidence for altered structure and function from optical and enzymatic studies. Biochim Biophys Acta1983; 744: 36–45.
17.
RichardtGFederolfGHabermannE. The interaction of aluminium and other metal ions with calcium-calmodulin-dependent phosphodiesterase. Arch Toxicol1985; 57: 257–9.
18.
AlfreyACLe GendreGRKaehryWD. The dialysis encephalopathy syndrome. Possible aluminium intoxication. N Engl J Med1976; 294: 184–8.
19.
PlattsMMGoodeGCHislopJS. Composition of the domestic water supply and the incidence of fractures and encephalopathy in patients on home dialysis. Br Med J1977; ii: 657–60.
20.
McClureJFazzalariNLFassettRGPugsleyDJ. Changes in bone histoquantitative parameters and histochemical staining reactions for aluminium in a group of patients with chronic renal failure following a reduction in the aluminium concentration of the haemodialysis fluid. J Clin Path1984; 37: 743–47.
21.
BoyceBFFellGSElderHY. Hypercalcaemic osteomalacia due to aluminium toxicity. Lancet1982; ii: 1009–12.
22.
OttSMMaloneyNACoburnJW. The prevalence of bone aluminium deposition in renal osteodystrophy and its response to calcitroil therapy. N Engl J Med1982; 307: 709–13.
23.
ThomasWCMeyorJL. Aluminium induced osteomalacia: An explanation. Am J Nephrol1984; 4: 201–3.
24.
LieberherrMGrosseBCournot-WitmesG. In vitro effects of aluminium on bone phosphatases: a possible interaction with PTH and vitamin D3 metabolites. Calcified Tissue Internal1982; 34: 280–4.
25.
CannataJBBriggsJDJunorBJR. Effect of acute aluminium overload on calcium and parathyroid hormone metabolism. Lancet1983; 501–3.
26.
CannCEPrussinSGGordonGS. Aluminium uptake by the parathyroid glands. J Clin Endocrinol Metab1979; 49: 543–6.
27.
MorrisseyJRothsteinMMayorGSlatopolskyE. Suppression of parathyroid secretion by aluminium. Kidney Int1983; 23: 699–704.
28.
De VernejoulMCde BelanguerRHalkidouH. Histomorphometric evidence of deleterious effect of aluminium on osteoblasts. Bone1985; 6: 15–20.
29.
AlbrightFKeifensteinEC. The Parathyroid Glands and Metabolic Bone Disease.Williams and Wilkins, Baltimore, 1948.
30.
BachraBNvan HarskampGA. The effect of polyvalent metal ions on the stability of a buffer system for calcification in vitro. Calcif Tissue Res1970; 4: 359–65.
ShortAIKWinneyRJRobsonJS. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication. Proc Eur Dial Transplant Ass1980; 17: 226–33.
33.
O'HareJAMurnaghanDJ. Reversal of aluminium initial hemodialysis anaemia by a low-aluminium dialysate. N Engl J Med1982; 306: 654–8.
34.
TouamMMartinezFLacourB. Aluminium-induced reversible microcytic anaemia in chronic renal failure: Clinical and experimental studies. Clin Nephrol1983; 19: 295–8.
35.
DruekeTTouamMLacourR. Possible relationship between RBC protoporphyrin and aluminium intoxication. Nephron1984; 38: 280.
36.
McGonigleRJSParsonsV. Aluminium-induced anaemia in haemodialysis patients. Nephron1985; 39: 1–9.
37.
CamJMLuckVAEastwoodJSde WardernerHE. The effect of aluminium hydroxide orally on calcium, phosphorus and aluminium metabolism in normal subjects. Clin Sci Mol Med1976; 51: 407–14.
38.
MajorGHReiserJAMakdaniDKuPK. Aluminium absorption and distribution: Effect of parathyroid hormone. Science1977; 197: 1187–9.
39.
WillsMRSavoryJ. Aluminium homeostasis. In: TaylorA, ed. Aluminium and Other Trace Elements in Renal disease.London: Baillière Tindall, 1986; 24–37.
40.
SlaninaPFreehWBernhardsonA. Influence of dietary factors on aluminium absorption and retention in the brain and bone of rats. Acta Pharmac Toxicol1985; 56: 331–6.
41.
GacekEMBabbALUvelliDA. Dialysis dementia. The role of dialysate pH in altering the dialysability of aluminium. Trans ASAIO1979; 25: 409–15.
42.
O'DonovanRHammerMBaldwinD. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet1986; i: 880–2.
43.
MorinierePRousselYTahiriA. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: Disappearance of hyperaluminaemia and control of hyperparathyroidism. Proc EDTA; 1982; 19: 784–7.
GrafHStummvollHKPragerR. Protein-binding and dialysate concentration of aluminium—the major determinants of aluminium kinetics during haemodialysis. In BrownSSSavoryJ, eds. Chemical Toxicology and Clinical Chemistry of Metals.New York: Academic Press, 1983; 357–60.
46.
PlattsMMAnastassiadesE. Dialysis encephalopathy: Precipitatory factors and improvement in prognosis. Clin Nephrol1981; 15: 223–8.
47.
AckrilPRalstonAJDayJPHodgeKC. Successful removal of aluminium from patients with dialysis encephalopathy. Lancet1980; ii: 693–4.
48.
MillinerDSNebekerHGOttSM. Use of desferoxamine infusion test in the diagnosis of aluminium-related osteodystrophy. Ann Intern Med1984; 101: 775–80.
49.
COM (85) 263 final of 29/5/85. Amended proposal for a council directive relating to the protection of dialysis patients by minimising the exposure to aluminium. Official J Europ Comm 20.6.85: C 150/6–C 150/15.
50.
BerlinA.Prevention and monitoring of aluminium exposure during dialysis in the European Community. In TaylorAP ed. Aluminium and Other Trace Elements in Renal Disease.London: Baillière Tindall, 1986; 167–70.
51.
TaylorAStarkeyBJWalkerAW. Determination of aluminium in serum: Findings of an external quality assessment scheme. Ann Clin Biochem1985; 22: 351–8.
52.
IoannouPCPiperakiEA. Kinetic fluorometric determination of aluminium in serum. Clin Chem1986; 32: 1481–3.
53.
GuillardOPiriouAMuraPReissD. Precautions necessary when assaying aluminium in serum of chronic haemodialysis patients. Clin Chem1982; 28: 1714–15.
54.
SubramanianKSChakerabartiCLSueirasFE. Preservation of some trace metals in samples of natural waters. Anal Chem1978; 50: 444–8.